.jpg "Audentes Therapeutics (NASDAQ: BOLD)")
In a report released today, Raju Prasad from William Blair maintained a Buy rating on Audentes Therapeutics (NASDAQ: BOLD). The company’s shares opened today at $35.88.
According to TipRanks.com, Prasad is a 4-star analyst with an average return of 19.3% and a 59.4% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Global Blood Therapeutics, and Krystal Biotech Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Audentes Therapeutics with a $39.80 average price target.
See today’s analyst top recommended stocks >>
Based on Audentes Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $25.57 million. In comparison, last year the company had a GAAP net loss of $22.74 million.
Based on the recent corporate insider activity of 16 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BOLD in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Audentes Therapeutics, Inc. is a biotechnology company, which engages on development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. Its products include AT001 for the treatment of X-Linked Myotubular Myopathy, AT002 for the treatment of Pompe disease, and AT003 for the treatment of Catecholaminergic Polymorphic Ventricular Tachycardia. The company was founded by Matthew R. Patterson and Thomas J. Schuetz on November 13, 2012 and is headquartered in San Francisco, CA.
